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Abstract
Background: Ghrelin receptor agonists have been established to be important in ameliorating the nutritional
conditions in patients with malnutrition. However, some studies have reported inconsistent results. We aimed to
coalesce the available evidence on the efficacy of ghrelin receptor agonists for the treatment of malnutrition.
Methods: We searched PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE for relevant
articles published through March 2016. Studies comparing the efficacy of ghrelin receptor agonists versus placebo
in malnourished patients were eligible for inclusion.
Results: A total of 12 studies involving 1377 patients were included. Compared with placebo, ghrelin receptor
agonists could increase the energy intake (standard mean difference [SMD] 2.67, 95% confidence interval [CI] 1.48
to 3.85, P < 0.001), lean body mass (weighted mean difference [WMD] 0.25 kg, 95% CI 0.07 to 0.42, P = 0.006), fat
mass (WMD 0.92 kg, 95% CI 0.05 to 1.8, P = 0.038), and grip strength (WMD 0.31 kg, 95% CI 0.207 to 0.414,
P < 0.001) of patients with malnutrition.
Conclusion: Our analysis indicated that ghrelin receptor agonists could improve the poor nutritional state of
malnourished patients by increasing their energy intake, ameliorating their irregular body composition and
improving their grip strength. However, these results might be less conclusive due to the limited sample sizes and
one potential publication that has not been released.
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Introduction
Malnutrition, a condition that is strongly associated with
poor prognosis, is a state of nutrition in which a deficiency
of energy, protein and micronutrients causes measurable
adverse effects on the body composition, function, and
clinical outcomes as well as unintentional weight loss [1].
Malnutrition is a common complication of many diseases,
such as chronic heart failure [2], chronic obstructive pul-
monary disease(COPD) [3], chronic renal failure(CRF) [4],
and cancer cachexia [5]. It may also result from other
causes of anorexia, sarcopenia or emaciation, including
anorexia nervosa [6], functional dyspepsia [7], and ageing
[8]. Thus, a single approach can not reverse all aspects of
these complicated syndromes and expect to provide
prominent benefits. A comprehensive intervention re-
quires the combination of nutritional support, pharma-
cotherapeutic methods, and exercise [9].
Ghrelin, a compound predominantly secreted by
gastric endocrine cells, is an endogenous ligand for the
growth hormone secretagogue receptor and has been
shown to increase growth hormone(GH) secretion from
the pituitary gland [10]. Ghrelin stimulates appetite and
food intake and triggers a positive energy balance
through GH-dependent mechanisms [11]. However, be-
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administered by either intravenous or subcutaneous in-
jection [12], the clinical applications of ghrelin are
restricted. Several orally active, and selective ghrelin
receptor agonists that have a longer half-life than ghrelin
were consequently developed, including anamorelin [13],
ibutamoren(MK-677) [14], ulimorelin(TZP-101) [15],
ipamorelin [16], relamorelin [17], and macimorelin [18].
A number of studies revealed that ghrelin receptor ago-
nists could stimulate appetite and food intake, improve
body composition and muscle wasting, and ameliorate
the disregulated nutritional condition in malnourished
patients. However, some studies have reported inconsist-
ent results [19–23]. In a recent report, Temel et al. dem-
onstrated that anamorelin could significantly increase
lean body mass (LBM) but could not significantly
enhance the grip strength of patients with cancer cach-
exia. Additionally, they did not report caloric intake [24].
Therefore, we performed this meta-analysis to confirm
the superiority of ghrelin receptor agonist administration
compared with placebo in malnourished patients. Our pri-
mary outcome was energy intake(EI), and the secondary
outcomes were LBM, fat mass(FM), and grip strength(GS).
Methods
We conducted this meta-analysis in accordance with
PRISMA guidelines [25] and the Cochrane Hand-
book for Systematic Reviews of Interventions [26]
following a registered protocol from the PROSPERO
database(CRD42016037466).
Searching strategy
PubMed, the Cochrane Central Register of Controlled
Trials (CENTRAL), and EMBASE were electronically
searched by independent investigators(JS and JG) to
identify any randomized controlled trial (RCT) published
through March 2016 that investigated the comparative
effects of ghrelin and its analogues versus placebo in pa-
tients with malnutrition. We used following search
terms embedded in specific files involving the title, key-
words, and abstract: “ghrelin”, “ghrelin receptor ago-
nists”, “malnutrition”, “under-nutrition”, “anorexia”,
“cachexia”, “weight loss”, and relevant variants of these
items. The search strings were constructed with a Bool-
ean operator. We also manually detected any eligible
studies among the references of identified papers and
several corresponding reviews to include any potential
studies, which would guarantee the precision and recall
ratio. No language or publication restrictions were
imposed. We did not assess the grey literature.
Identification of studies
The inclusion criteria were described according to the
PICOS acronym (participant, intervention, comparison,
outcomes of interest, and study design). For population
(P), all of the malnourished patients who were treated
with ghrelin receptor agonists were included in this
study. For intervention(I) and comparison (C), the stud-
ies investigated the comparative effects of ghrelin recep-
tor agonists versus placebo. For outcome of interests
(O), we accessed the following outcomes: EI, LBM, FM
and GS. Regarding the study design (S), only RCT with
or without blind methodology were considered.
The exclusion criteria were as follows: healthy volun-
teers; subjects under 18 years old; patients with either
normal nutrition or obesity; a lack of essential informa-
tion; animal studies; a review, letter or specialist
comment; and non-RCT.
Data extraction
Two independent investigators (JS and YT) extracted
the baseline information and essential data of the ex-
pected outcomes from each study, including the last
name of the first author, publication year, country, sam-
ple size of each group, average age and body mass
index(BMI) of participants, disease status of the included
patients, interventional protocol, follow-up, and reported
outcomes of interest. We contacted the authors to
acquire any missing data when necessary. Any diver-
gence was resolved by either consensus or consultation
with a third author (JB).
Accessing the quality of methodology
Two independent investigators (HY and ML) were
assigned to critically appraise the methodological quality
of all eligible studies in accordance with the Cochrane
Handbook of Systematic Review of Interventions. Seven
indexes were independently assessed, and the following
results were crosschecked: randomization sequence gen-
eration, allocation concealment, blinding of participants
and study personnel, blinding of outcome assessors,
incomplete outcome data, selective reporting, and other
biases. The risk of each incorporated study was rated as
“ high bias risk ” ,“ unclear bias risk ” or “ low bias risk ”
according to the extracted information. A third investi-
gator (JB) was assigned to resolve any disagreement.
Statistical analysis
Stata 12.0 software (Stata Corp, College Station, Texas,
USA) was employed to analyse the pooled effect of EI
with the SMD and 95% CI, and of the LBM, FM, and GS
with WMD and 95% CIs. Heterogeneity was assessed
using the χ2-base Q test with a p < 0.10 and the I2 test
with I2 > 50% suggesting significant heterogeneity [27].
We preferentially used the fixed effects model (Mantel-
Haenszel method) for pooled analysis [28]; if high het-
erogeneity was identified, we used the random effects
model (DerSimonian and Larid method) [29]. Given the
considerable heterogeneity, we also performed sensitivity
Su et al. Nutrition Journal  (2016) 15:97 Page 2 of 10
analyses by excluding each study to evaluate the contri-
bution of the inclusion of studies for heterogeneity. Pub-
lication bias was estimated using Egger’s test and funnel
plots with the trim and fill method [30, 31], which were
also utilized to adjust for publication bias from potential
unpublished studies. Statistical significance was consid-
ered when a 2-tailed P value was less than 0.05.
Results
Figure 1 shows the flow diagram for study selection. We
identified 785 potentially relevant studies based on
above search strategy at the initial search stage. After
screening the title and abstract, 20 studies were selected
for the full-text assessment, and eight trials were ex-
cluded due to several reasons such as lack of interested
outcomes, ineligible control regimens, and non-RCTs.
All selection procedures were performed independently
by two investigators. Finally, 12 eligible studies [13, 20,
24, 32–39] were incorporated into this meta-analysis.
Studies characteristics
The 12 included RCTs comprised 1377 patients, includ-
ing 1008 male subjects and 369 females. Among the
total cohort, 854(62%) patients were assigned to the
ghrelin receptor agonists group, and 523(38%) to the
control group. The sample size ranged from 14 to 495
subjects, and the follow-up ranged from one day to
12 weeks. All of the included studies compared the effi-
cacy of ghrelin receptor agonists with a corresponding
placebo. Nine studies enrolled patients with cancer,
while the other three studies did not. Seven studies ad-
ministered ghrelin, whereas the remaining five trials
used anamorelin. The basic characteristics of included
studies are shown in Table 1.
Risk of bias in the included studies
We carefully appraised the methodological quality of the
included studies according to the Cochrane Collabora-
tion’s Risk of Bias Tool. Four studies provided detailed
information regarding the seven total indexes. In the
remaining studies, varying degrees of methodological
bias were identified. All of the included trials were rated
as low bias risk regarding incomplete outcome data be-
cause the authors described the drop-out reasons in de-
tail and used the intent-to-treat method to analyse the
data. No other bias sources were identified. The graph-
ical results of the methodological quality are shown in
Figs. 2 and 3.
Energy intake
Eight studies reported the EI data: seven measured the
total calories of ingested food, whereas the eighth esti-
mated the total calories by using a calorie count. In total,
201 participants were included for the pooled analysis,
which showed a significantly increased EI after adminis-
tration of ghrelin receptor agonists (SMD 2.67, 95%CI
1.48 to 3.85, P < 0.001, Fig. 4). There was significant het-
erogeneity among the studies (I2 = 89.3%, P < 0.001).
Subgroup analyses showed that the increased EI after
the administration of ghrelin receptor agonists remained
evident irrespective of the different areas, diseases,
therapeutic drug, and follow-up.
Sensitivity analyses showed no alterations of the main
outcome after eliminating each study. However, we
found no significant heterogeneity when we excluded
the studies that did not include cancer patients(I2 = 0%,
P = 0.99) with a new pooled SMD of 1.12 (95%CI 0.74 to
1.50, P < 0.001).
Egger’s test was statistically significant (P = 0.037) and
visual inspection of the funnel plot seemed to be asym-
metric. The trim and fill method suggested that there
might be one unpublished studies (Fig. 5). Using trim
and fill method, we found that our finding remained
significant after adjusting for one unpublished study(SMD
2.18, 95%CI 0.913 to 3.448, P = 0.001).
Lean body mass
A total of six studies comprising 1178 participants
reported LBM data as measured by dual energy x-ray
absorptiometry(DEXA). The meta-analysis showed that
administration of ghrelin receptor agonists could in-
crease the LBM in malnourished patients (WMD
0.25 kg, 95%CI 0.07 to 0.42, P = 0.006, Fig. 6). There was
also significant heterogeneity among the studies regard-
ing LBM (I2 = 95.2%, P = 0.000). The subgroup analyses
showed that increased LBM after administration of
785 studies identified
765 excluded based on abstract
20 studies retrieved for detailed assessment
8 studies excluded:
4 were observational trials
3 investigated the high and low dose of 
ghrelin, and the control group was
not administration of placebo
1 did not have the outcome of interest
12 studies included in meta-analysis
(1377) patients
Fig. 1 Flow diagram of the retrieval and selection of
qualifying literature
Su et al. Nutrition Journal  (2016) 15:97 Page 3 of 10
ghrelin receptor agonists remained evident irrespective
of the different regions, diseases, or therapeutic drug.
Sensitivity analyses showed no alterations of the main
outcome after eliminating each study. However, we
found no significant heterogeneity when excluded the
study by Miki (I2 = 43%, P = 0.14) with a pooled WMD
of 1.64 kg (95%CI 1.31 to 1.97, P < 0.001). Egger’s test re-
vealed no statistical significance (P = 0.054), indicating
that there is no publication bias.
Fat mass
There were four studies(923 subjects) that reported FM
data, which was also measured by DEXA. The meta-
analysis revealed that administration of either ghrelin
or anamorelin to malnourished patients could increase
the FM (WMD 0.92 kg, 95%CI 0.05 to 1.8, P = 0.038)
with no evidence for heterogeneity across the studies
(I2 = 0%, P = 0.938, Fig. 7). We found no change of the
pooled estimate effect and heterogeneity after sensitivity
Table 1 Basic Characteristics of the Included Studies Comparing Ghrelin Receptor Agonists versus Placebo















Neary 2004 [36] UK 7/7 54.3 ± 8.4/
54.3 ± 8.4
cancer 22.6 ± 4.1/22.6 ± 4.1 Grelin(5 pmol/kg.min), IVP,
single dose
placebo 1 day EI
Wynne 2005 [38] UK 9/9 49.8 ± 5.2/
49.8 ± 5.2
CRF 24.7 ± 4.4/24.7 ± 4.4 Ghrelin(3.6 nmol/kg), HD,
single dose
placebo 3 days EI
Ashby 2009 [33] UK 12/12 49.4 ± 14.6/
49.4 ± 14.6
CRF 24.3 ± 4.1/24.3 ± 4.1 Ghrelin(12 μg/kg), HD, qd,
7 days
placebo 7 days EI
Yamamoto 2010 [39] Japan 10/10 63 ± 6/
65 ± 6
cancer 20 ± 2/22 ± 4 Ghrelin(3 μg/kg), IVP, bid,
10 days
placebo 10 days EI
Shinichi 2010 [32] Japan 10/10 64.8 ± 10.4/
61.6 ± 8.4
cancer 23.1 ± 3.1/24.5 ± 3.8 Ghrelin(3 μg/kg), IVP, bid,
10 days
placebo 10 days EI, LBM,
FM
Miki 2012 [20] Japan 18/15 70.5 ± 6.2/
73.9 ± 6.0
COPD 18.6 ± 2.1/18.0 ± 2.1 Ghrelin(2 μg/kg) , IVP, bid,
3 weeks
placebo 3 week EI, LBM,
FM, GS
Hiura 2012 [35] Japan 20/20 65.8 ± 5.2/
61.8 ± 10.9
cancer 21.6 ± 3/21.0 ± 2.7 Ghrelin(3 μg/kg), IVP, bid,
7 days
placebo 7 days EI
Garcia 2012 [13] USA 16/16 61.9 ± 10.29/
62.9 ± 8.43
cancer 22.1 ± 3.51/21.6 ±
3.93
Anamorelin, 50 mg, PO,
qd, 3 days
placebo 3 days EI
Garcia 2015 [34] USA 44/38 65.5 ± NR/
65 ± NR
cancer 21.5 ± NR/21.1 ± NR Anamorelin, 50 mg, PO,
qd, 12 weeks
placebo 12 weeks LBM, FM,
GS
Takayama 2016 [37] Japan 55/60 65.7 ± 8.8/
66 ± 9.4
cancer 20.23 ± 3.21/19.80
± 2.86
Anamorelin, 100 mg, PO,
qd, 12 weeks
placebo 12 weeks LBM, GS
Temel 2016(1) [24] USA 323/161 63 ± NR/
63 ± NR
cancer 23.2 ± 3.6/23.3 ± 3.7 Anamorelin, 100 mg, PO,
qd, 12 weeks
placebo 12 weeks LBM, FM,
GS
Temel 2016(2) [24] USA 330/165 63 ± NR/
62 ± NR
cancer 22.5 ± 3.7/22.1 ± 3.7 Anamorelin, 100 mg, PO,
qd, 12 weeks
placebo 12 weeks LBM, FM,
GS
Abbreviations: SD standard deviation, NR not reported
Fig. 2 Assessment of the risk of bias: bias of risk graph
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analyses. Egger’s test revealed no statistical significance
(P = 0.633), showing that there is no publication bias.
Grip strength
A total of five studies comprising 1085 participants
reported GS data: two of the studies measured handgrip
strength on each side by using a hand-held dynamom-
eter, while the other three only measured the handgrip
strength of the non-dominant hand. The meta-analysis
showed that administration of ghrelin receptor agonists
could increase the GS in malnourished patients (WMD
0.31 kg, 95%CI 0.21 to 0.41, P < 0.001, Fig. 8). Sensitivity
analyses showed no alterations of the main outcome
after eliminating each study. However, we found no sig-
nificant heterogeneity when we excluded the study by
Garcia (I2 = 0%, P = 0.43), with a pooled WMD of 0.3 kg
(95%CI 0.19 to 0.4, P < 0.001). Egger’s test revealed no
statistical significance (P = 0.501), indicating that there is
no publication bias.
Discussion
In the present study, we demonstrated that administra-
tion of ghrelin receptor agonists could ameliorate the
nutritional condition of patients with malnutrition by
increasing their food intake, changing their body com-
position, and enhancing their muscle strength. These
conclusions were strengthened by the fact that sensitivity
analyses and the trim and fill method did not alter these
outcomes, although there might be lack of power to
detect differences with the limited sample size and other
potential publications. There was significant heterogen-
eity in the pooled analyses of EI and LBM. Therefore, we
used a subgroup analysis and sensitivity analysis to iden-
tify the causes of heterogeneity. When we excluded the
Fig. 3 Assessment of the risk of bias: bias of risk summary
Fig. 4 Forest plot of energy intake
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studies that had no cancer patients enrolled, the high
degree of heterogeneity vanished. Thus, the differences
in patients’ diseases might be the cause of the significant
heterogeneity.
Loss of appetite appears in many patients with severe
malnutrition, which is not only frequent, but is also
associated with a poor prognosis and reduced quality of
life [40]. In this study, we found that administration of
ghrelin receptor agonists could increase energy intake,
which confirms their well-established role in stimulating
appetite and increasing food intake [41, 42]. Administra-
tion of exogenous ghrelin administration was first noted
to promote food intake and weight gain in rats [43, 44].
These effects were independent of the effects of ghrelin
on GH stimulation and the GH secretagogue recep-
tor(GHS-R) and might be related to neuropeptide
Y(NPY), as indicated by the increase of plasma NPY
levels after IV bolus of ghrelin [45]. Another possible
explanation is that ghrelin could inhibit the production
of the anorectic proinflammatory cytokines such as
interleukin-1β, interleukin-6, and tumour necrosis fac-
tors, as well as induce secretion of the anti-inflammatory
cytokine interleukin-10 [46]. In contrast, in a random-
ized, double-cross-over clinical study, Strasser et al. used
different doses of ghrelin in cancer patients and found
that the nutritional intake did not increase following
ghrelin administration [19]. Moreover, a single ghrelin
infusion could not increase the food intake in patients
with postvagotomy diarrhoea [22] and anorexia nervosa
[23], although repeated infusions could stimulate hunger
and food intake in these subjects [6, 32]. Thus, we
postulated that the dose and frequency of ghrelin admin-
istration to the enrolled subjects would influence the
actual clinical effect. Interestingly, the increase in energy
Fig. 5 Funnel plot with the trim and fill method for energy intake
Fig. 6 Forest plot of lean body mass
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intake following ghrelin administration occurred without
compensatory undereating [47] or evidence of tachy-
phylaxis [33]. However, the included studies evaluated EI
by different methods, so we used SMD as the effect
magnitude, which was less persuasive than WMD.
Changes in body composition that develop with
chronic diseases are usually considered unwanted and
are associated with the loss of muscle, fat mass, or both
[48]. The loss of lean and fat tissue may be associated
with weight loss; such involuntary weight loss has been
termed cachexia [49]. Activation of the GHS-R exerted
anabolic functions and could lead to weight gain [41].
Ghrelin receptor agonists could increase bodyweight by
not only stimulating appetite but also by decreasing en-
ergy expenditure, the latter of which was relevant to
cancer cachexia [50]. Our results validated the capacity
of ghrelin receptor agonists in improving the body com-
position of patients with under-nutrition as indicated by
the significant increase in LBM and FM. Low LBM was
associated with a poor prognosis and could predict the
toxic effects of treatment [51]. Increased FM reflected
improved energy balance, although GH secretion
induced by ghrelin receptor agonists may contribute to
low adiposity [52]. Thus, the present study illuminated
the beneficial effect of ghrelin receptor agonists on the
positive changes in body composition and weight gain,
Fig. 7 Forest plot of fat mass
Fig. 8 Forest plot of grip strength
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which would be promising for the treatment of malnu-
trition, as losses in body weight and sarcopenia are
characteristic features of under-nutrition [53].
Theoretically, a valid treatment for cachexia-associated
muscle wasting should increase muscle mass and, as a
consequence, enhance muscle strength. However, muscle
wasting in cachectic patients results from a variety of
factors such as age-related muscle atrophy, therapies
targeting the primary disease, comorbidity, and persist-
ent systematic inflammation [24]. Contrary with cortico-
steroids [54] and progestational drugs [55], which were
commonly prescribed as orexigenic agents and could
only increase appetite and body weight, our findings
verified that ghrelin receptor agonists could significantly
enhance muscle strength. Activation using ghrelin recep-
tor agonists induced GH secretion, thereby increasing
the insulin-like growth factor-1 (IGF-1) concentration;
GH and IGF-1 could promote muscle growth through a
direct effect on the muscle and indirectly activating the
production of both muscle-restricted IGF-1 and anti-
cachectic cytokines [56]. However, our included studies
investigated muscle function by measuring handgrip
strength with either the dominant or non dominant
hand, which measured upper-extremity strength and
might not indicate a comprehensively physiological per-
formance. Further studies using internationally validated
methods to assess muscle strength are warranted.
An important concern with regard to the application
of ghrelin receptor agonists in cancer cachexia is that
they may increase the levels of growth factors such as
GH and IGF-1 to promote tumour growth. In addition,
ghrelin itself may have mitogenic potential. Northrup et
al. evaluated ghrelin and anamorelin on tumour growth
in mouse models of lung cancer, and found that neither
compound could effect tumour growth until the end of
the intervention despite the significantly increased GH
and IGF-1 levels [57]. Additionally, clinical studies with
anamorelin [58] and ghrelin [59] have also shown no sig-
nificant effect on overall survival compared with pla-
cebo. Long-term, large-scale clinical trials are required
to determine whether treatment with ghrelin receptor
agonists could stimulate tumour growth [60].
There are some limitations in this meta-analysis. First,
the basic characteristics of the included patients differed
in some confounders. However, sensitivity analysis and
the trim and fill method did not alter the results of our
primary outcome, which lessened the adverse effect due
to this limitation. Second, the sample size of included
studies was small, the follow-up was short, and only two
ghrelin receptor agonists were analysed among the
variety of agonists in existence. Third, there were more
male patients than females in each group, so the conclu-
sions were less conclusive for female subjects. Further
studies with more subjects, a longer follow-up period
and implementation of different ghrelin receptor ago-
nists are required to identify whether the administration
of ghrelin receptor agonists would lead to long-term
benefits such as reduced total medical cost, decreased
hospital stay, and elevated quality of life and overall
survival.
Conclusion
In conclusion, based on the results of our meta-analyses,
we confirmed that administration of ghrelin receptor ag-
onists could have beneficial effects on patients with mal-
nutrition. This novel approach, which directly targets
appetite stimulation, could have an important role in the
future management and prevention of under-nutrition
for malnourished patients.
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